Phillip Morris International (PM) urges FDA advisory committee to recommend authorising Zyn as modified-risk tobacco

Phillip Morris International (PM) urges FDA advisory committee to recommend authorising Zyn as modified-risk tobacco.

Philip Morris International urging the FDA to classify Zyn as a modified-risk tobacco product could open the door for wider acceptance and sales growth in a well-defined market segment. This move emphasizes PM's strategic pivot towards reduced-risk products, which may positively influence investor sentiment and impact the overall tobacco sector as regulatory landscapes evolve.